Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24393065 | 0.78 | EGFR (0.40) | TRPA1KDR | |
| SCHEMBL3521904 | 0.76 | ALDH1A1 (0.36) | MKNK1TRPA1MAP4K4AAK1 | |
| SCHEMBL30836076 | 0.76 | ALDH1A1 (0.36) | MKNK1TRPA1MAP4K4AAK1 | |
| SCHEMBL2778073 | 0.76 | MAP4K4 (0.45) | MAP4K4 | |
| SCHEMBL24188641 | 0.76 | MAP4K4 (0.34) | MKNK1MAP4K4KDR | |
| SCHEMBL29728027 | 0.76 | MAP4K4 (0.45) | MAP4K4 | |
| SCHEMBL14521105 | 0.72 | PARP1 (0.44) | MKNK1ACHE | |
| SCHEMBL21179488 | 0.72 | BCHE (0.36) | BCHEACHE | |
| SCHEMBL30823293 | 0.72 | BCHE (0.36) | BCHEACHE | |
| SCHEMBL17490355 | 0.71 | AAK1 (0.42) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013050527-A1 | QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-04-11 | — | — | WO | claimed |
| WO-2013050527-A1 | QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-04-11 | — | — | WO | disclosed |
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | MKNK1 351/4885TRPA1 3038/4885MAP4K4 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.